Pura Vida Investments LLC lowered its stake in shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) by 11.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 180,198 shares of the biopharmaceutical company’s stock after selling 22,291 shares during the period. Pura Vida Investments LLC’s holdings in Catalyst Pharmaceuticals were worth $346,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Northern Trust Corp increased its stake in shares of Catalyst Pharmaceuticals by 9.7% during the second quarter. Northern Trust Corp now owns 1,107,944 shares of the biopharmaceutical company’s stock valued at $3,458,000 after buying an additional 97,997 shares during the period. Los Angeles Capital Management & Equity Research Inc. grew its stake in Catalyst Pharmaceuticals by 152.9% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 42,900 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 25,940 shares during the period. JPMorgan Chase & Co. grew its stake in Catalyst Pharmaceuticals by 9.6% in the third quarter. JPMorgan Chase & Co. now owns 989,080 shares of the biopharmaceutical company’s stock worth $3,739,000 after purchasing an additional 86,692 shares during the period. Bank of New York Mellon Corp grew its stake in Catalyst Pharmaceuticals by 12.3% in the third quarter. Bank of New York Mellon Corp now owns 308,580 shares of the biopharmaceutical company’s stock worth $1,166,000 after purchasing an additional 33,767 shares during the period. Finally, BlackRock Inc. grew its stake in Catalyst Pharmaceuticals by 3.2% in the third quarter. BlackRock Inc. now owns 6,251,780 shares of the biopharmaceutical company’s stock worth $23,633,000 after purchasing an additional 192,153 shares during the period. 47.83% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Patrick J. Mcenany bought 20,000 shares of the business’s stock in a transaction dated Wednesday, December 19th. The shares were purchased at an average cost of $2.24 per share, with a total value of $44,800.00. Following the completion of the purchase, the insider now owns 4,737,693 shares in the company, valued at approximately $10,612,432.32. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Donald A. Denkhaus bought 25,000 shares of the business’s stock in a transaction dated Thursday, December 27th. The stock was bought at an average cost of $1.91 per share, for a total transaction of $47,750.00. Following the completion of the purchase, the director now owns 225,000 shares of the company’s stock, valued at approximately $429,750. The disclosure for this purchase can be found here. Corporate insiders own 9.30% of the company’s stock.

Several equities research analysts recently weighed in on CPRX shares. Cantor Fitzgerald set a $8.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 28th. Oppenheimer set a $6.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 29th. BidaskClub cut Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, December 5th. Piper Jaffray Companies upped their price target on Catalyst Pharmaceuticals from $5.00 to $7.50 and gave the stock an “overweight” rating in a research note on Thursday, December 13th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, December 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $6.35.

NASDAQ CPRX opened at $2.98 on Friday. Catalyst Pharmaceuticals Inc has a 12 month low of $1.85 and a 12 month high of $4.05. The firm has a market capitalization of $308.22 million, a PE ratio of -14.19 and a beta of 2.32.

COPYRIGHT VIOLATION WARNING: “Pura Vida Investments LLC Lowers Position in Catalyst Pharmaceuticals Inc (CPRX)” was originally published by Marea Informative and is the property of of Marea Informative. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.mareainformativa.com/news/2019/03/17/pura-vida-investments-llc-lowers-position-in-catalyst-pharmaceuticals-inc-cprx.html.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Featured Article: Marijuana Stocks Future Looks Bright

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals Inc (NASDAQ:CPRX).

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.